# An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.

> **NCT00528996** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 2080 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** BEA 2180 BR
- **DRUG:** Tiotropium Bromide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00528996
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09-06
- **Primary completion:** 2009-05-05
- **Final completion:** 2009-05-05
- **Target enrollment:** 2080 (ACTUAL)
- **Last updated:** 2021-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00528996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00528996, "An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00528996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*